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ABSTRACT 
Bivalent chromatin domains, containing active H3K4me3 and repressive H3K27me3 histone 
marks, define gene sets poised for expression or silencing following embryonic stem (ES) 
cell differentiation. Previous work has suggested that aberrantly poised genes in cancer cells 
may facilitate changes in transcriptional state following drug exposure. We have used ChIP-
seq to characterize genome-wide positioning of H3K4me3 and H3K27me3 associated 
chromatin in primary high-grade serous ovarian carcinoma and normal ovarian surface and 
fallopian tube tissue. Sets of genes with proximal bivalent marks were defined using this 
data and subsequently evaluated as signatures of systematic change in DNA methylation 
and gene expression between pairs of tissue samples taken from patients at primary 
presentation and relapse following chemotherapy. 
The set of genes harbouring bivalent chromatin domains at their promoters in tumour, but 
not normal epithelia, overlaps significantly with Polycomb-repressive complex target genes, 
as well as transcriptionally silenced genes in normal ovarian and tubal stem cells. The 
bivalently marked genes identified in tumours before chemotherapy have increased 
promoter CpG methylation and reduced gene expression at relapse following chemotherapy 
of ovarian cancer.  
This work supports the hypothesis that pre-existing histone modifications associated with 
genes in a poised chromatin state may lead to epigenetic silencing by DNA methylation 
during acquired drug resistance and suggests targets for intervention approaches to prevent 
drug resistance emerging.  
 
  
INTRODUCTION 
 
Genetic information is packaged into human cells in the form of chromatin: double-stranded 
molecules of DNA wrapped around complexes of histone proteins. Covalent modifications of 
the histone tails can alter the density of compaction of chromatin, which can influence the 
accessibility of DNA to the transcription machinery that is required for gene expression. The 
Polycomb repressive complex (PRC2), suppresses target gene expression through 
catalysing the trimethylation of Lysine 27 of the histone protein H3 (H3K27me3)(1). This 
modified histone forms broad domains that are enriched at repressed genes(2). PRC2-null 
mouse Embryonic Stem (ES) cells can be derived, but do not contribute to viable organisms, 
so it is widely accepted that PRC2 and H3K27me3 play an important role in the 
differentiation of pluripotent cells. In ES cells, genomic loci bound by the core PRC2 
members (SUZ12, EED and EZH2) tend to display both the repressive mark H3K27me3 and 
permissive mark H3K4me3 (trimethylation of Lysine 4 of the histone protein H3). These 
'bivalent' promoters, simultaneously containing both active and repressive histone marks, 
are strongly enriched for genes whose expression either rapidly increases or rapidly 
decreases upon differentiation from ES cells(3). Recent physical evidence supports the co-
occurrence of both H3K4me3 and H3K27me3 on the same nucleosomes, and demonstrates 
resolution of bivalent domains upon differentiation(4). This leads to current understanding 
that these marks indicate genes 'poised' for response to some differentiation or selective 
stimulus.  
 
Aberrant gene silencing, leading to inactivation of tumour-suppressors and dysregulation of 
cell growth, has long been regarded an important feature of carcinogenesis(5). More 
recently, it has been shown to play an active role in the acquisition of drug resistance(6). 
While a large body of work in this area focuses on methylation of cytosines in DNA (CpG 
methylation), evidence also implicates histone modifications, particularly H3K27me3, as a 
means of aberrant gene silencing in cancer. These two mechanisms are known to be 
linked(7), and genes associated with bivalent marks in ES cells are enriched in genes with 
promoter CpG hypermethylation in cancers(8). A further observation linking PRC2 with 
cancer, and particularly to cancer stem cells, is that the histone methyltransferase 
component of PRC2, EZH2, is overexpressed in tumour-initiating subpopulations of ovarian 
cancer cell lines, and inhibition of EZH2 inhibited tumour growth(9). High EZH2 expression 
has been associated with poor outcomes in a range of cancer types(10, 11). 
 
We previously showed that a primary high-grade serous ovarian tumour had bivalent 
chromatin domains enriched for loci that are bivalently marked in ES cells, but additionally at 
loci detected only in the tumour(12). These bivalently marked genes were preferentially 
silenced in tumour-initiating subpopulations of an ovarian cancer cell line and in the 
platinum-resistant isogenic pair of a platinum-sensitive ovarian cancer cell line. This 
suggests that the acquisition of stem cell associated bivalent chromatin domains could 
provide tumour cells a mechanism for rapid adaptation to drug exposure, with expression 
changes made more persistent through acquisition of DNA methylation. The involvement of 
these epigenetic alterations in cancer cell populations may result from adaptation of normal 
cellular differentiation involved in tissue maintenance and regeneration, and could link the 
process of tumour initiation to later acquired drug resistance(6). It is therefore relevant that a 
definitive stem cell populations from both ovarian and fallopian tube epithelia have recently 
been characterized(13). 
 
We have now generated histone modification profiles from further primary high-grade serous 
ovarian tumours and from normal ovarian tissue in an attempt to shed light on the role of 
bivalent chromatin domains in ovarian carcinogenesis and acquired drug resistance in 
patients. A schematic summary of our approach and our key findings are shown in Figure 1. 
As would be expected, there is variation in the sets of H3K27me3 and H3K4me3 marked 
genes from tumour to tumour. However, we show that the expanded common set of genes 
bivalently marked in ovarian tumours is strongly enriched for the canonical PRC2 target 
genes associated with differentiation. Importantly, we use paired tumour samples taken from 
a cohort of patients before and after the acquisition of platinum resistance to show that these 
bivalently-marked PRC2 target genes are predisposed towards epigenetic silencing via gain 
of DNA methylation following chemotherapy, during acquired drug resistance of patients’ 
tumours. Drug resistance leads to treatment failure and overcoming resistance is one of the 
greatest unmet needs in ovarian cancer. We propose that therapeutics targeting aberrant 
PRC2 activity in tumour cells during remission could prevent acquisition of resistance by 
DNA methylation to widely-used cytotoxic chemotherapies and offer a means of preventing 
drug resistance emergence. 
 
  
MATERIALS AND METHODS 
 
Sample collection 
Four high-grade serous epithelial ovarian tumour samples from untreated patients at primary 
presentation, three normal ovarian surface epithelium samples and one normal fallopian 
tube epithelium sample were obtained from the Hammersmith Hospital Ovarian Cancer 
Tumour Bank. Tumour collection for this study was approved by local Ethics Committee and 
informed written consent was obtained from patient. 
 
Chromatin immunoprecipitation, sequencing and PCR 
All ChIP-seq sample processing and library preparation was performed as previously 
described(12). ChIP libraries were sequenced using an Illumina HiSeq2000 at the CSC 
Genomics Core Laboratory of Imperial College London. Individual 50bp reads were filtered if 
they contained 5 base calls with quality Phred score less than 30, or if they contained any 
undetermined bases. The remaining reads were mapped to the hg19 reference genome 
using Bowtie2(14). Reads were further filtered so that a maximum of one uniquely-mapped 
read was kept for each genomic co-ordinate. All reads mapping to the DAC Consensus 
Excluded Regions were discarded and cross-correlation for each filtered sequence library 
was calculated as described(15) across a range of inter-strand offsets from 1 to 200bp, at 
5bp intervals. Locations of significant peaks of enriched DNA in each of the ChIP samples 
were identified using MACS v1.4.2(16) using a p-value cutoff of 1e-4. 
IP-enrichment of candidate regions was confirmed through qPCR of IP chromatin from the 
high-grade serous ovarian cancer cell line PEA1. Cells were crosslinked with 1% 
formaldehyde and processed according to (17). Briefly, chromatin extract were sonicated 
using a Diagenode sonicator using 20 cycles (30 s on and 30 s off) at maximum intensity. 
Purified chromatin was then immunoprecipitated using 4 μg of H3K4me3 (Abcam 8580) or 
H3K27me3 (Abcam 6002) antibodies per ChIP. Non-immunoprecipitated chromatin was 
used as Input control. PCR primer sequences are given in Supplementary Table S3. IP 
enrichment was calculated as ௜௡௣௨௧_஽ே஺௖௢௡௖஼௛ூ௉_஽ே஺௖௢௡௖ 2ି∆஼௧, where ∆ܥݐ denotes the difference in 
amplification Ct values between input DNA and antibody pull-down DNA. 
 
Assessing differential methylation and expression in clinical samples 
All DNA methylation data was taken from ovarian tumour and ascites samples from the 
ICGC study(18) profiled on the Illumina 450k HumanMethylation arrays. 11 paired primary-
relapse samples were available from which the primary sample was tumour but the paired 
relapse sample was from ascites, and 1 pair where tumour material from relapse was also 
obtained. In addition, 3 pairs of tumour and ascites samples both taken at primary 
presentation were available.  To account for tissue-specific methylation differences between 
tumour cells and ascites, differential methylation was evaluated in terms of the fold-increase 
in methylation M-values between primary and relapse samples for each pair, divided by the 
average fold-increase in methylation M-values between tumour and ascites pairs. For 
differential gene expression, log-transformed, normalized FPKM RNA-seq counts were 
obtained for each gene from the ICGC ovarian cancer study(18). Statistics for differential 
expression were calculated using LIMMA(19) with a linear model term for each patient, a 
term to model tissue-specific differences and a term to model differences from primary to 
relapse. Empirical Bayes moderated t-statistics were obtained for the primary-vs-relapse 
coefficient for each gene. 
 
Bisulphite Pyrosequencing 
A total amount of 500 ng of genomic DNA was bisulphite modified using the Zymo Research 
EZ-DNA Methylation Kit (Cambridge Bioscience) according to the manufacturer's 
instructions. Sequences of pyrosequencing primer sets are provided in Supplementary Table 
S3. Pyrosequencing PCR was performed in duplicate for each sample in a 25 μl volume 
containing an end-concentration of 1 U Faststart Taq polymerase (Roche, Welwyn Garden 
City, UK), 1x FastStart PCR Buffer including 2 µM MgCl2 (Roche), 0.05 mm dNTPs (Roche), 
0.4 µM primers (each) adding 1 μl of modified DNA template using the following conditions: 
95 °C for 6 min, 45 cycles of 95 °C for 30 s, 58 °C for 30 s, 72 °C for 30 s, followed by 72 °C 
for 5 min and terminating at 4°C. Pyrosequencing of PCR products was performed on 
PyroMark Q 96 MD using the PyroGold Reagent Kit (Qiagen) according to the 
manufacturer's instructions. The methylation percentage of CpG sites for individual genes 
was calculated by using the Pyro Q-CpG software (version 1.0.9), Biotage (Uppsala, 
Sweden). 
 
Statistical analysis 
Hypergeometric test refers to use of the hypergeometric distribution in R to calculate the 
probability of at least as great an observed overlap between two sets of genes occurring 
purely by chance. 
Pearson Correlation Coefficients and their corresponding significance estimates were 
calculated in R. 
The ‘GeneSetTest’ function in the Limma package(19) from Bioconductor was used to 
evaluate the statistical significance of a systematic shift of a set of genes towards an 
increase (or decrease) in measurements between two groups of samples measured in a 
molecular profiling experiment. 
Module Maps(20) were used to create signature scores for each sample, summarizing the 
level of gene expression or DNA methylation across a set of genes or CpG loci, respectively. 
Functional annotation of poised, hypermethylated genes was carried out using DAVID 
according to described protocol(21). 
Assessment of statistical significance of observed increase in DNA methylation estimates 
from pyrosequencing of PEA1 and PEA2 cell lines was performed using the binomial 
distribution implemented in R, with null hypothesis based on an assumed probability of 0.5 of 
each locus showing higher methylation in PEA2 than PEA1. 
 
Availability of data and material 
ChIP-seq data for 4 primary tumour samples and 4 normal tissue samples, along with 
microarray data from 4 primary tumour samples, will be made available through Gene 
Expression Omnibus (accession number to be confirmed). RNA-seq and DNA methylation 
data from ICGC ovarian cancer patients at primary presentation and relapse are available 
from the ICGC Data Portal (https://icgc.org/icgc/cgp/67/304/809). All processed datasets, 
annotation resources and data analysis code will be made available for public access on the 
first author’s Imperial College website (http://www.imperial.ac.uk/people/e.curry). 
 
 
  
RESULTS 
 
Bivalent chromatin marks in primary ovarian tumours associate with gene silencing 
Chromatin was extracted from 4 primary High Grade Serous Ovarian tumours, 3 healthy 
ovarian surface epithelium samples and 1 fallopian tube epithelium sample. Following 
extraction, Chromatin Immunoprecipitation (IP) in conjunction with high-throughput 
sequencing (ChIP-seq) was performed (as described in materials and methods) to identify 
genome-wide positioning of the permissive histone mark H3K4me3 and the repressive mark 
H3K27me3. Regions of significant enrichment of IP over input DNA control, referred to as 
'peaks,' were computed for each sample and each histone mark using MACS(16). Genes 
with peaks in both active and repressive histone marks lying within 2kb of their TSS were 
called bivalently-marked. All samples showed evidence of bivalent promoters, with all tumour 
samples showing significantly more genes carrying bivalent marks than would be expected 
from random overlap of the individual active and repressive marks (see Supplementary 
Information). The number of bivalently marked genes in each sample is markedly correlated 
(Pearson Correlation Coefficient 0.856, p=0.0067) to the number of genes marked with 
H3K27me3 in each sample, but not H3K4me3. That is, samples with more bivalently-marked 
genes tend to have more H3K27me3-marked genes, but not more H3K4me3-marked genes, 
than samples with fewer bivalently-marked genes. This suggests that the H3K27me3 mark is 
more critical in creating the bivalent chromatin state, supporting the well-established links 
between PRC2 and repression of gene expression at bivalent promoters. It also suggests 
that the set of bivalently-marked genes in each profiled tissue is only a subsample of the full 
complement that could have been observed. This motivated us to identify regions of the 
genome that show a disposition toward bivalency across multiple tumours but not in the 
normal tissue samples. 
 
Combining this with the set of bivalently marked genes from a previous experiment(12) gave 
us a list of  genes with evidence for poised promoter chromatin states in multiple primary 
high-grade serous ovarian tumours, but not in normal ovarian surface or fallopian epithelia 
(provided in Supplementary Table S1). 
 
Previous work showed that genes with bivalent promoters were more likely to be 
transcriptionally silenced in the profiled tumour than genes with active promoter marks(12). 
Applying the same analysis strategy to gene expression microarray data obtained from the 
tumours that were used for ChIP-seq profiling of bivalent chromatin, the average proportion 
of present, marginal and absent detection calls for all probe-sets mapping to bivalently-
marked genes were compared against the proportions for probe-sets mapping to genes with 
H3K4me3 mark only. Genes with bivalently-marked promoters were significantly less likely to 
be expressed at a detectable level (Chi-squared test p<2.2e-16), suggesting that the set of 
bivalently-marked genes are representative of a degree of functional epigenetic silencing. 
 
Poised genes in primary tumours are enriched for regulators of cell fate 
Genes marked with bivalent promoters in ES cells are considered to be key determinants of 
differentiation  pathways, being in a poised state that retains the capacity to either increase 
or decrease transcription rates rapidly when required. The genes harbouring proximal 
bivalent chromatin domains in the ovarian tumours analysed are highly enriched for 
Polycomb targets with poised promoters in ES cells (Hypergeometric test p=5.8e-100, PRC2 
targets obtained from (22)). Although the cell of origin of serous ovarian cancers remains 
contentious with both ovarian surface and fallopian tube epithelia being suggested(23, 24), a 
recent study provided molecular characterization of a definitive ovarian and fallopian tube 
epithelial stem cell population in the mouse, marked by expression of Lgr5(13). The set of 
genes with bivalently-marked chromatin in the ovarian tumour samples was significantly 
enriched for human orthologs of genes that were downregulated in the Lgr5+ stem cell 
compartment relative to Lgr5- comparison (Hypergeometric test p= 0.006). As there was no 
such enrichment for orthologs of the genes upregulated in Lgr5+ cells, it would appear that 
repression of transcription of genes marked with bivalent chromatin in ovarian tumour cells 
would keep the cells in a more 'stem-cell like' state, but maintaining the capacity to lose stem 
cell associated features rapidly as and when required. Table 1 displays a summary of the 
numbers of genes in each set. 
 
Bivalent chromatin domains and DNA hypermethylation during acquisition of drug resistance 
To examine the hypothesis that bivalent promoters in tumours at presentation may 
predispose genes towards hypermethylation during acquisition of drug resistance, we have 
integrated our ChIPseq data with RNA expression and DNA methylation data generated by 
the International Cancer Genome Consortium (ICGC) of high grade serous ovarian cancer, 
including paired samples from patients both at primary, chemo-naïve, presentation and upon 
relapse following platinum-based chemotherapy(18). It has previously been shown that key 
differentiation genes bivalently marked with promoters in ES cells are predisposed toward 
hypermethylation during tumour development(8, 25). Consistent with this, the set of 
promoters we identify that have hypermethylation in primary tumours relative to normal 
fallopian tube tissue samples show enrichment for ES Polycomb target genes (Limma Gene 
Set Test p=0.01). Further, we see an enrichment of the ES Polycomb targets among the set 
of genes which gain promoter CpG methylation at drug-resistant relapse compared to 
primary chemo-naïve tumours (Hypergeometric test p=2.1e-08). These ES Polycomb target 
genes also show a systematic downregulation of gene expression from primary to relapse 
samples (Limma Gene Set Test p=6.0e-10). Genes with proximal CpG loci gaining 
methylation, compared to all genes, show a significant systematic downregulation of gene 
expression from primary to relapse samples (Limma Gene Set Test p=3.5e-05), arguing that 
the gain of DNA methylation is associated with the reduction in expression. 
 
To evaluate systematic changes of promoter CpG methylation following chemotherapy 
across genes marked with bivalent chromatin domains in primary, chemo-naïve, ovarian 
tumour cells, we calculated the average change in CpG methylation between matched 
primary and relapse samples from the same patient. Comparing the corresponding 
distribution for loci in bivalently-marked promoters with that of all promoter CpGs, we see a 
systematic shift towards greater hypermethylation (t-test p=0.036, Supplementary Figure 
S1). We computed Module Map scores(20) to summarize promoter CpG methylation across 
entire gene sets in each sample for illustration in the heatmap in Figure 2A, with average 
module map scores across primary and relapse samples shown in Figure 2B. To further 
demonstrate that this effect was due to more hypermethylation and not less 
hypomethylation, we extracted only those loci with greater than 2-fold average increase in 
methylation in relapse samples compared to primary tumours (given in Supplementary Table 
S2), and found that this set was enriched for the set of promoters with bivalent chromatin 
domains identified by ChIPseq in primary ovarian tumours (Hypergeometric test p=0.004). 
Functional annotation of the list of genes that are both bivalently marked and show at least 
2-fold increase in DNA methylation upon relapse suggests a link between this 
hypermethylation and a suppression of cellular differentiation (GO terms ‘pattern 
specification process’ and ‘cell fate commitment’ were enriched with adjusted p-values 7.2e-
8 and 1.9e-4, respectively, a full table of enriched GO terms is provided in Supplementary 
Table S4). Some of the samples are observed to have clearer systematic promoter 
hypermethylation of these target genes than others. In fact there is considerable 
heterogeneity, both within the primary and the relapse tumours, in the levels of DNA 
methylation for even the gene set representing the most consistently differentially-
methylated between the groups. This may arise from multiple alternative mechanisms for 
silencing being employed in the tumours, as found in (26). 
 
In primary tumour and relapse pairs taken from the ICGC patient cohort (n=10), gene 
expression profiling by RNA-seq data shows a systematic down-regulation of the set of 
genes marked with bivalent chromatin domains in primary ovarian tumour cells (Limma 
Gene Set Test p=0.037). We computed Module Map scores to summarize expression levels 
across entire gene sets in each sample for illustration in the heatmap in Figure 2C, with 
average module map scores across primary and relapse samples shown in Figure 2D. 
Interestingly we also see that the orthologs of Lgr5-downregulated genes in the mouse 
ovarian stem cell model show a strong systematic down-regulation of expression in relapsed 
samples relative to primary tumours (Limma Gene Set Test p<1e-12). This latter observation 
implies that tumour cells upon relapse have a more stem-cell-like gene expression profile 
and that bivalent chromatin marks may provide a mechanism for the observation that high 
grade serous ovarian cancer cells enhance stem cell like characteristics following exposure 
to chemotherapy(8) (9). The individual PRC2 complex members EZH2, EED and SUZ12 all 
showed higher median expression in the relapse samples relative to primary samples, but 
this difference was only statistically significant in the case of SUZ12 (paired t-test p=0.025). 
Further, we saw significant overexpression of DNMT3B (p=0.047), which suggests that 
transcriptional upregulation of this de novo DNA methyltransferase may be involved 
mechanistically in the observed epigenetic silencing of bivalently-marked genes. 
 
A set of candidate loci from the bivalently-marked genes showing hypermethylation on 
relapse were selected for independent evaluation in the PEA1/PEA2 isogenic cell line pair. 
Bivalent marks at promoters for DXL5, TRIM7, CYP21B1 and HOXD10 in the primary 
tumour derived cell line PEA1 were confirmed through ChIP-qPCR. Fold-enrichment from IP 
with antibodies targeting each of H3K4me3 and H3K27me3, relative to input DNA, is shown 
in Figure 3A. All selected loci show marked enrichment of the target regions through both 
H3K4me3 and H3K27me3 ChIP. Levels of DNA methylation for CpG sites in these promoters 
were assayed through bisulphite pyrosequencing, in both primary tumour derived cell line 
PEA1 and the cell line PEA2, which was derived from the same patient as PEA1 but after 
chemotherapy and subsequent relapse (27). Methylation levels (an average of 2 technical 
replicates) for these CpG sites are presented in Figure 3B, showing an increase in 
methylation in PEA2 relative to PEA1 for 10 of the 13 loci. Assuming under randomness that 
each CpG site would have a 50% chance of being measured at a higher level in PEA2 
relative to PEA1, we have p=0.011 for seeing that many loci hypermethylated in PEA2 purely 
by chance. This independent evaluation supports the systematic promoter hypermethylation 
of bivalently-marked genes that we established based on analysis of patient samples. 
  
DISCUSSION 
 
We previously proposed a model in which overexpression of EZH2 in cancer cells, 
particularly those with lower proliferation rate and greater tumorigenic capacity, leads to 
aberrant marking of promoters with bivalent chromatin domains, predisposing these loci to 
epigenetic silencing via DNA methylation during the course of tumour evolution towards an 
acquired drug resistant state(6). We previously presented evidence of bivalent chromatin 
domains in a primary ovarian tumour, showed that these were enriched for Polycomb targets 
associated with developmental regulation, and linked the bivalently marked genes to 
transcriptional silencing in tumour-initiating cell enriched subpopulations and chemotherapy-
resistant models of ovarian cancer cell lines(12). However, access to paired tissue samples 
from patients prior to and after exposure to chemotherapy in our present study allowed us to 
demonstrate systematic epigenetic silencing of bivalently marked gene sets occurring in 
patients in the course of treatment. During this time, the cancer cells have been exposed to 
chemotherapy and have both regrown a tumour mass and altered their drug sensitivity so 
that the same cytotoxic chemotherapy is less effective at therapeutic doses. This applies 
both to bivalent genes defined from primary HGSOC tumours compared against normal 
ovarian and tubal epithelia, and to canonical Polycomb targets defined in ES cells, which 
gives assurance that the gene sets analysed are not overly dependent on data from 
individual subjects. Given that we see lower expression of Lgr5-downregulated orthologs in 
relapse tissue, and functional annotation of the genes found to be bivalently-marked and 
hypermethylated upon relase points to a signature associated with cell fate specification, we 
believe that epigenetic reprogramming associated with drug resistant relapse could reflect a 
more stem-like phenotype through suppression of differentiation. 
 
With available data we cannot differentiate between poised states leading to the acquisition 
of silencing during chemotherapy, as opposed to bivalently marked loci already being fully 
silenced in (drug-resistant) clones within the primary tumour sample which survived and 
grew out following initial treatment to form the relapse. The only way to address this 
definitively would be to use single-cell genetic and epigenetic profiling of all tumour samples, 
which remains technically infeasible at this time. It also remains to be demonstrated whether 
or not any of the epigenetic silencing events we have observed are directly contributing to 
the functional acquisition of drug resistance in high grade serous ovarian cancer cells, 
although our set of genes with bivalent promoters in tumours included FLNC and MDK, 
previously identified key drivers of epigenetically-mediated acquisition of drug resistance in 
ovarian tumour cell line models(28). Proof of a direct causal link would require further 
experimental evidence. Such experiments would require emergence of epigenetic editing 
technology (e.g. (29)) to induce the presence or absence of bivalent marks at PRC2 target 
gene promoters, then follow an appropriate model through acquisition of drug resistance, 
monitoring changes to DNA methylation and gene expression. As such technology is still in 
development, experimental proof of causality is beyond the scope of this study. 
 
Importantly, we have shown that the histone modification profile from a primary tumour at 
initial clinical presentation is informative of the DNA methylation and gene expression state 
of drug-resistant tumour at relapse many months after treatment.  This suggests that drug-
resistant disease could theoretically be targeted before it develops, through a personalized 
medicine strategy that utilizes epigenetic profiles obtained from a primary tumour sample to 
predict the most likely drivers of subsequent resistance.  Alternatively, it may be the case 
that the epigenetic silencing events are acquired during chemotherapy and only in a poised 
state at presentation, a scenario that might be implied by the observation of overexpression 
of the PRC2 complex member SUZ12 and the de novo DNA methyltransferase DNMT3B on 
drug-resistant relapse. In such a scenario, epigenetic therapies such as histone 
methyltransferase or DNA methyltransferase inhibitors could be used in the maintenance 
setting during remission to prevent the emergence of drug resistance. 
 
Our data also supports cancer stem cells as being important in carcinogenesis and tumour 
evolution. We have shown here that ovarian tumour cells harbour the bivalent chromatin 
domains that are characteristic of pluripotent cells held in an undifferentiated state poised to 
undergo rapid phenotypic change on lineage commitment. Specifically, we see poised 
chromatin states leading to epigenetic silencing of genes involved in stem cell differentiation, 
implying this disruption of normal differentiation processes as a potential mechanism by 
which tumour cells could adapt to the presence of cytotoxic chemotherapy. Promoters kept 
in a poised state by the presence of these domains would enable cells not immediately killed 
by cytotoxic chemotherapy to adapt to the changes in their environment brought about by 
this treatment, and repopulate a tumour with cells re-programmed to suppress cellular 
mechanisms of drug sensitivity and treatment response. In this context we highlight the 
observation that mouse Lgr5+ stem cells of the ovary and fallopian tube overexpress Ezh2 
relative to the Lgr5- differentiated ovarian and tubal epithelia(13). Tumour-initiating 
subpopulations of human cancer cell lines with stem cell-like properties also overexpress 
EZH2 relative to non-tumour initiating subpopulations(9). If both the normal adult stem cell 
compartment of the ovary and tumour initiating cells of ovarian cancers overexpress the 
enzyme responsible for deposition of the H3K27me3 histone mark, which is a key step in 
formation of bivalent chromatin domains, it may suggest that this mechanism is already 
present in the normal physiology of the ovary. This, in turn, would indicate that high grade 
serous ovarian cancers are physiologically disposed towards this capacity for epigenetically 
driven acquired drug resistance. Treatment failure of ovarian cancer patients due to the 
emergence of drug resistant tumours is a major clinical obstacle in the management of this 
disease. If overexpression of Polycomb genes is a feature of a stem cell state and allows 
adaptive silencing of genes upon drug exposure, it would suggest that inhibiting PRC2 
activity in ovarian tumour initiating subpopulations could reduce the capacity of cancer cells 
to persist through cytotoxic onslaught, and reduce the rate of emergence of tumours that 
develop resistance to chemotherapy.  
 
In conclusion, we have shown that high grade serous ovarian cancer at initial presentation 
have bivalently marked chromatin domains, containing active H3K4me3 and repressive 
H3K27me3 histone marks, which define gene sets that are more likely to have increased 
promoter CpG methylation and reduced gene expression at patient relapse with resistant 
disease. This provides the first evidence from patient samples that epigenetic silencing 
during acquired drug resistance could be underpinned by pre-existing histone modifications 
associated with genes being in a poised state and suggests potential interventional 
approaches that prevent the emergence of drug resistance. 
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 Table 1: Summary of numbers of genes with bivalent marks in ovarian tumour and 
normal tissues 
Tissue Source Bivalently Marked 
Genes  
ES Polycomb 
Targetsa 
(out of 1567) 
Ovarian Lgr5 
Targetsb 
(out of 203) 
Ovarian Tumour 747 217 11 
Normal (OSE, 
FT) 
207 23 3 
a. Previously described Polycomb targets in ES cells(22) 
b. Orthologs of genes downregulated in Lgr5+ mouse ovary cells(13). 
 
 
  
FIGURES 
 
Figure 1 – Graphical Summary of Analytical Approach and Key Findings 
 
ChIP-seq for H3K27me3 and H3K4me3 (in comparison to input DNA) was used to obtain 
genome-wide bivalent mark profiles in 4 primary ovarian tumours and 4 normal tissue 
samples, supplemented by the profile from a primary ovarian tumour obtained from our 
previous study. Genes with both H3K27me3 and H3K4me3 marks within 2kb of the TSS in 
any of the tumours but none of the normal tissues were taken forward as representative of 
poised genes in primary ovarian cancers. These genes systematically gained methylation 
and reduced expression in ovarian cancer patient samples obtained at relapse following 
cytotoxic chemotherapy treatment, relative to their primary tumour samples. The set of 
genes which were both poised in primary tumours and epigenetically silenced upon relapse 
were strongly enriched for regulators of differentiation, including the classical ES cell 
Polycomb targets.  
Figure 2 – Module Maps Summarizing DNA Methylation and Gene Expression 
Signatures 
 
Heatmaps show module map scores for gene sets in terms of DNA methylation (A) and gene 
expression (C) in individual primary tumour and relapse ascites samples from the ICGC 
high-grade serous ovarian cancer cohort. Set of genes with bivalent chromatin domains in 
ovarian tumours is labelled ‘tumour.bivalent’, set of polycomb targets in ES cells is labelled 
‘prc2’, set of orthologs of genes repressed in Lgr5+ mouse ovary stem cells is labelled 
‘lgr5.targets’, sets of genes up- and down-regulated in expression in relapse ascites relative 
to primary tumours are labelled ‘relapse.hi’ and ‘relapse.lo’ respectively, and sets of genes 
hyper- and hypo-methylated in relapse ascites relative to primary tumours are labelled 
‘relapse.hyper’ and ‘relapse.hypo’ respectively. Colour bar along top of the heatmaps 
indicates primary samples with blue and relapse samples with pink. Average module map 
scores across all primary samples (blue) and all relapse samples (pink) are shown in bar 
charts (B) for DNA methylation and (D) for gene expression. These show that methylation 
tends to increase in relapse for the genes with bivalent marks in primary ovarian tumours, for 
the polycomb targets in ES cells and for genes decreasing expression on relapse. 
Methylation tends to decrease in relapse for the genes increasing expression on relapse. 
Gene expression shows the opposite trend, decreasing for the genes with bivalent marks in 
primary ovarian tumours and for the polycomb targets in ES cells. 
 
  
Figure 3 – Evaluation of bivalent chromatin marks and hypermethylation in 
PEA1/PEA2 ovarian cancer cell line model 
 
(A) Fold-enrichment from H3K4me3 and H3K27me3 immunoprecipitation of PEA1 cell line 
DNA at promoter regions of candidate genes, based on ChIP-qPCR quantification. Each IP 
shown is an average of two independent chromatin extractions, pull-down and amplification. 
Values shown reflect concentration of target region DNA relative to all DNA in the sample, 
normalized to no-IP input DNA. (B) Quantification of promoter CpG methylation levels in 
PEA1 and PEA2 cell lines by bisulphite pyrosequencing. Values shown represent proportion 
of sequenced DNA fragments with the corresponding CpG site methylated, out of all 
sequenced DNA fragments mapping to that CpG site. Each assay reflects the average of two 
technical replicates. 
 
  
SUPPLEMENTARY DATA 
 
Supplementary Table S1 - Bivalent Gene Set 
List of genes featuring bivalent chromatin domains within 2kb of annotated TSS (as 
described by Ensembl) in any of the profiled primary ovarian tumours but not any of the 
profiled normal ovarian surface or fallopian tube epithelium samples. 
 
Supplementary Table S2 – Hypermethylated Bivalent Genes 
List of genes containing the subset of genes listed in Table S1 that additionally show at least 
2-fold average increase in methylation between relapse and primary ovarian cancer cells for 
at least one promoter CpG locus. 
 
Supplementary Figure S1 - DNA Methylation Change in Relapse Cancer Cells Relative 
to Primary Tumours 
Density plot showing distributions of median log fold-changes in DNA methylation between 
primary tumour samples and relapse ascites samples, normalized by the tissue-specific 
effect (change from primary tumour samples to primary ascites samples). This distribution 
for all promoter CpG loci measured on the Illumina HumanMethylation 450k arrays is shown 
with the black line, the distribution for CpG loci mapping to promoters of our bivalently-
marked gene set is shown with the red line. T-test shows that bivalently-marked promoter 
CpGs show significantly more gain in methylation from primary to relapse samples, with 
p=0.036. 
 
Supplementary Table S3 - Primers 
Tables of primer sequences used for PCR of ChIP-enriched DNA and for pyrosequencing of 
bisulphite-treated DNA. 
 
Supplementary Table S4 - GeneOntologyEnrichments 
Table of Gene Ontology Biological Process terms enriched in the set of bivalently-marked 
and relapse-hypermethylated genes from this study. 
 
Supplementary Information 
Further details of computational analysis of ChIP-seq libraries provided in document  
 
OvCaBivalentAnalysis.R  
R script used to generate outputs presented in the manuscript. 
 
